About
Canndoc is developing pharma-grade cannabis products. Over the years, Canndoc has provided more than 500,000 doses to 15,000 patients, demonstrating expertise across the value chain from research, cultivation, and processing to product development and good manufacturing practice (GMP) clinical trial pipeline initiation. Driven by the mission of meeting patients' needs and improving their quality of life, Canndoc's GMP-standard products are prescribed for a range of indications including neuropathic pain, pain from cancer, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's disease, and epileptic seizures. Canndoc is a fully owned subsidiary of Israeli Medical Cannabis, Intercure. Its products and genetics cover European, Canadian, and Israeli regulatory requirements.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was CANNDOC Pharma acquired and by which company?
- CANNDOC Pharma was acquired by InterCure in September 2018.
- What is CANNDOC Pharma's primary focus?
- CANNDOC Pharma focuses on developing pharma-grade cannabis products.
- What is the employee count for CANNDOC Pharma?
- CANNDOC Pharma has 7 employees.
- In which geographic markets does CANNDOC Pharma operate?
- CANNDOC Pharma operates in Israel, Canada, and Europe.
- Which company signed a long-term partnership agreement with CANNDOC in March 2020?
- CANNDOC signed a long-term partnership agreement with Super-Pharm in March 2020.
- What strategic agreement did Organigram and CANNDOC sign in June 2020?
- Organigram and CANNDOC signed an International Strategic Agreement in June 2020.
- Which company expanded into Israel through a strategic alliance with InterCure, owner of CANNDOC, in December 2020?
- Charlotte's Web expanded into Israel through a strategic alliance with InterCure, owner of CANNDOC, in December 2020.
- What was the news regarding CANNDOC in January 2021?
- In January 2021, news reported that Israeli Cannabis Company Canndoc was to go public via SPAC.
- What was the development concerning CANNDOC's former CEO in September 2019?
- In September 2019, the former Major General stepped down as CEO of cannabis cultivator Canndoc.